Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if giving 17-hydroxyporgesterone caproate (17 OHPC) to
mothers with preeclampsia diagnosed before 34 weeks gestation improves mother and baby
outcomes.